Sugi Predict

Sugi Predict / Compounds / SCHEMBL712993

SCHEMBL712993

SCHEMBL712993

COC(=O)c1cc(OCC(=O)OC(C)(C)C)cc(OCc2ccccc2F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.47
▸ GCK P35557 2/20 0.46
▸ RARA P10276 1/20 0.46
▸ RARB P10826 1/20 0.46
▸ RARG P13631 1/20 0.46
▸ PTPN1 P18031 1/20 0.46
▸ PARP15 Q460N3 2/20 0.44
▸ PARP10 Q53GL7 2/20 0.44
▸ PARP14 Q460N5 1/20 0.44
▸ LMNA P02545 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ MAPT P10636 3/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ SCN9A Q15858 1/20 0.40
▸ KAT6A Q92794 1/20 0.39
▸ SCN3A Q9NY46 1/20 0.39
▸ HPD P32754 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712175 0.85 GCK (0.53) MAOBGCKRARARARBRARG
SCHEMBL14505835 0.85 MAOB (0.59) MAOBGCKRARARARBRARG
SCHEMBL711371 0.84 MAOB (0.56) MAOBGCKRARARARBRARG
SCHEMBL14002247 0.81 ATM (0.46) LMNAMAPTKMT2APOLBCYP2C9
SCHEMBL14505834 0.80 GCK (0.57) MAOBGCKRARARARBRARG
SCHEMBL4585887 0.80 CA12 (0.53) LMNAMAPTMEN1KMT2APOLB
SCHEMBL12615603 0.80 GCK (0.63) MAOBGCKRARARARBRARG
SCHEMBL10206851 0.79 LMNA (0.47) MAOBGCKRARARARBRARG
SCHEMBL2650147 0.78 MAOB (0.52) MAOBGCKRARARARBRARG
SCHEMBL5353265 0.76 SMN1; SMN2 (0.53) ALDH1A1MAPTMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 — — EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 — — US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 — — EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK MAOB 1046/4885GCK 1/4885RARA 3613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.